Abbott Laboratories stock (US0028241000): analysts stay positive as new diabetes data and steady gains draw attention

Abbott Laboratories stock has attracted renewed attention in recent days as new data from its Healthy Food Rx program for diabetes patients and fresh analyst commentary highlight how the healthcare group is positioning itself across diagnostics, medical devices, nutrition and branded generics. The shares have also been grinding higher over the past month, which keeps the stock on the radar for US investors looking at large-cap healthcare names, according to MarketBeat as of 05/31/2026 and a summary of the Healthy Food Rx study reported by GuruFocus as of 05/31/2026.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

Abbott Laboratories: core business model

Abbott Laboratories is a diversified healthcare group whose business model spans several segments, including medical devices, diagnostics, nutrition products and established pharmaceuticals. The company generates revenue by developing, manufacturing and selling products such as glucose monitoring systems, cardiovascular and neuromodulation devices, in vitro diagnostic tests, infant and adult nutrition brands and branded generic drugs in various geographies, as described in investor materials and segment discussions summarized by Abbott investor relations as of 04/17/2026.

The medical devices division includes technologies like continuous glucose monitoring systems that help people with diabetes track their glucose levels, alongside cardiovascular devices and structural heart products. Diagnostics covers core laboratory tests, point-of-care systems and rapid diagnostics used in hospitals, clinics and other settings to support patient care and decision-making, according to segment overviews cited by Abbott company information as of 04/17/2026.

Nutrition is another major pillar, with Abbott supplying pediatric nutrition brands for infants and children as well as adult nutrition products used in both consumer and clinical environments. The established pharmaceuticals business focuses primarily on branded generics in emerging markets, providing medicines in areas such as cardiovascular and metabolic health. This diversified setup aims to balance growth opportunities in innovative medical technologies with more stable, recurring demand from diagnostics and nutrition, based on product descriptions compiled by Abbott company information as of 04/17/2026.

Main revenue and product drivers for Abbott Laboratories

A key growth driver for Abbott in recent years has been its continuous glucose monitoring portfolio within the medical devices segment, which addresses the expanding global diabetes market. These systems allow patients to track glucose levels in real time and have been a focus of innovation and marketing efforts, especially in the United States and Europe, according to commentary on business trends in diabetes technology summarized by GuruFocus as of 05/31/2026.

Diagnostics is another significant revenue contributor, with Abbott supplying a wide range of laboratory instruments and test kits used for routine blood tests, infectious disease detection and other clinical applications. These products generate recurring revenue through reagents and consumables, which can support more predictable cash flows when installed bases grow. The pandemic period accelerated demand for certain rapid tests, although that contribution has normalized, according to management commentary in past filings summarized by Abbott investor relations as of 02/07/2025.

Abbott’s nutrition business, meanwhile, focuses on both pediatric and adult nutritional products that cater to health and wellness trends. Sales in this area are influenced by demographics, consumer preferences and healthcare policy, particularly in North America and other developed markets. Established pharmaceuticals, concentrated in emerging economies, round out the portfolio and provide exposure to growing middle-class demand for branded generic drugs, as outlined in the company’s geographic breakdown of revenues cited by Abbott investor relations as of 02/07/2025.

Healthy Food Rx program puts diabetes outcomes in focus

Beyond its devices and diagnostics, Abbott has also been highlighting its Healthy Food Rx program, which links tailored food support and coaching to better diabetes outcomes. New research associated with the initiative showed that participants receiving healthy food boxes and coaching experienced improved health markers and reduced food insecurity compared with control groups, according to a summary of study results reported by StockTitan citing Abbott research as of 05/29/2026.

The Healthy Food Rx concept is designed to address social determinants of health by pairing medical technology and data with practical nutritional support for people with diabetes who may also face food insecurity. In the latest research, participants in the program reportedly showed stronger health outcomes than in earlier phases of the initiative, reinforcing the potential for broader rollout and partnerships with health systems and payers, based on the findings referenced by GuruFocus as of 05/31/2026.

For investors, the program is notable because it illustrates how Abbott can leverage its expertise in diabetes technology, data and nutrition to influence outcomes beyond traditional device sales. While the Healthy Food Rx initiative is not broken out as a separate revenue line, it could support long-term demand for continuous glucose monitoring systems and nutrition products if payers and healthcare providers increasingly integrate food-as-medicine concepts into chronic disease management, according to the program discussion cited by StockTitan as of 05/29/2026.

Recent stock performance and valuation context

In equity markets, Abbott Laboratories shares have seen a gradual uptrend over the past month. The stock traded around 90.46 USD at the latest close, representing a gain of roughly 7.4% over the past 30 days, according to price history data from MarketBeat as of 05/31/2026. This move has occurred against a backdrop of broader market volatility, keeping the company in focus for investors seeking defensive growth exposure in healthcare.

Valuation metrics show Abbott trading at a price-to-earnings ratio in the mid-20s, with a market capitalization around 157.7 billion USD and a dividend yield close to 2.8%, based on a recent snapshot of the stock and dividend profile reported by Investing.com as of 05/27/2026. Some valuation frameworks suggest the shares may trade below their estimated intrinsic value, but such models rely on assumptions about future growth and profitability that can change over time, as highlighted by a fair value comparison on GuruFocus as of 05/31/2026.

Technical analysis indicators for Abbott are mixed but show the stock trading near or slightly above certain moving averages on a short-term basis, which some traders interpret as a sign of bullish momentum. However, technical signals can shift quickly with market sentiment, and they are just one component among many when evaluating a large-cap healthcare stock, according to chart-based analytics for ABT on Barchart as of 05/31/2026.

Analyst perspectives and dividend profile

Sell-side analysts have generally maintained a constructive view on Abbott Laboratories. For example, a Wells Fargo analyst recently reiterated a buy rating on the stock with a target price of 109 USD, reflecting expectations for continued growth in key segments such as medical devices and diagnostics, according to a summary of the rating action reported by Moomoo citing Wells Fargo research as of 05/20/2026.

Other institutions have echoed a positive stance, with Goldman Sachs also maintaining a buy rating on Abbott, citing the company’s diversified portfolio and exposure to structural healthcare trends, according to a rating summary from InsiderMonkey citing Goldman Sachs as of 05/16/2026. Consensus expectations typically bake in continued growth in diabetes technology and a recovery from pandemic-driven volatility in diagnostics volumes.

In addition to analyst commentary, Abbott’s dividend track record remains a point of interest. The company pays a regular cash dividend that currently equates to a yield in the high-2% area and has a history of increases over time, according to dividend data presented by Investing.com as of 05/27/2026. For income-focused investors, the combination of dividend payments and potential earnings growth can be a key element of the equity story in the US market.

Why Abbott Laboratories matters for US investors

Abbott Laboratories plays a significant role in the US healthcare ecosystem through its presence in hospitals, clinics, pharmacies and consumer channels. Its diagnostics and medical devices are widely used in the United States, while its nutrition brands occupy shelf space in major retailers and healthcare facilities, underscoring its visibility in everyday healthcare consumption, based on product and market descriptions from Abbott company information as of 04/17/2026.

From a portfolio perspective, the stock offers US investors exposure to several healthcare growth themes, including innovation in diabetes management, aging populations, and the expansion of diagnostics and nutrition in both developed and emerging markets. Since the shares trade on the NYSE in US dollars, they can be readily accessed through US brokerage platforms and retirement accounts, making Abbott a frequent component of diversified healthcare or dividend-oriented strategies, as reflected in its inclusion in various US equity indices highlighted by MarketBeat as of 05/31/2026.

The company’s ability to generate cash flows across multiple segments may also be relevant for investors who monitor resilience through economic cycles. While demand for elective procedures can fluctuate, diagnostics and nutrition businesses tend to display more stable characteristics. For US investors in particular, Abbott’s mix of growth, income via dividends and underlying exposure to healthcare demand both domestically and globally is often analyzed in the context of broader sector allocation decisions.

Conclusion

Abbott Laboratories sits at the intersection of several key healthcare trends, combining a diversified business model with a growing presence in diabetes management and diagnostics. Recent data from its Healthy Food Rx program underscores how the company is exploring new ways to improve outcomes for people with chronic conditions, while analyst ratings and stock performance reflect continued interest from the market. For US investors, the stock offers exposure to global healthcare demand, recurring revenue streams and a longstanding dividend profile, but as with any equity investment, future returns will depend on execution, regulatory developments and broader market conditions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.